Sanofi India Limited
NSE: SANOFI BSE: SANOFI
Prev Close
6221.5
Open Price
6261
Volume
21,446
Today Low / High
6232 / 6331
52 WK Low / High
4902 / 10524.95
Range
5,991 - 6,622
Prev Close
6222.95
Open Price
6293.9
Volume
2,845
Today Low / High
6232 / 6330
52 WK Low / High
4145.9 / 10526.05
Range
5,991 - 6,622
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 6306.5 (target range: 5,991 - 6,622), reflecting a change of 85 (1.36623%). On the BSE, it is listed at 6306.45 (target range: 5,991 - 6,622), showing a change of 83.5 (1.34181%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Sanofi India Limited Graph
Sanofi India Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Sanofi India Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 6,306.50, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 6,306.45 | 6,369.51 | 5,732.56 - 7,006.47 |
6,432.58 | 5,146.06 - 7,719.09 | ||
6,495.64 | 4,546.95 - 8,444.34 | ||
Bearish Scenario | 6,306.45 | 6,243.39 | 5,619.05 - 6,867.72 |
6,180.32 | 4,944.26 - 7,416.39 | ||
6,117.26 | 4,282.08 - 7,952.43 |
Overview of Sanofi India Limited
ISIN
INE058A01010
Industry
Drug Manufacturers - General
Vol.Avg
27,085
Market Cap
145,238,695,000
Last Dividend
117
Official Website
IPO Date
2002-07-01
DCF Diff
1,813.50
DCF
4,493
Financial Ratios Every Investor Needs
Stock Dividend of SANOFI
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2025-04-25 | April 25, 25 | 117 | 117 | 2025-04-25 | 2025-06-14 | |
2024-05-03 | May 03, 24 | 117 | 117 | 2024-05-03 | 2024-05-24 | |
2024-03-07 | March 07, 24 | 50 | 50 | 2024-03-07 | 2024-03-20 | |
2023-04-28 | April 28, 23 | 194 | 194 | 2023-04-28 | 2023-06-10 | |
2022-08-05 | August 05, 22 | 193 | 193 | 2022-08-08 | 2022-08-22 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-12-31 | 2,013.20 Cr | 979.30 Cr | 1,033.90 Cr | 0.5136 | 0.00 Cr | 0.00 Cr | 454.10 Cr | 413.30 Cr | 179.45 | 471.10 Cr | 0.2053 |
2023-12-31 | 2,851.10 Cr | 1,257.40 Cr | 1,593.70 Cr | 0.5590 | 0.00 Cr | 371.70 Cr | 1,219.30 Cr | 602.90 Cr | 261.78 | 886.80 Cr | 0.2115 |
2022-12-31 | 2,770.10 Cr | 1,189.60 Cr | 1,580.50 Cr | 0.5706 | 0.20 Cr | 74.90 Cr | 734.00 Cr | 620.60 Cr | 269.47 | 907.90 Cr | 0.2240 |
2021-12-31 | 2,924.60 Cr | 1,306.80 Cr | 1,617.80 Cr | 0.5532 | 0.40 Cr | 80.40 Cr | 763.60 Cr | 944.40 Cr | 410.06 | 1,326.10 Cr | 0.3229 |
2020-12-31 | 2,868.80 Cr | 1,253.60 Cr | 1,615.20 Cr | 0.5630 | 0.30 Cr | 75.00 Cr | 723.50 Cr | 477.60 Cr | 207.38 | 761.20 Cr | 0.1665 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-12-31 | 283.80 Cr | 1,611.80 Cr | 751.20 Cr | 860.6000 Cr | 19.30 Cr | -264.50 Cr | 499.80 Cr | 329.30 Cr | 0.00 Cr | 0.00 Cr | -43.50 Cr | 719.2000 Cr |
2023-12-31 | 394.50 Cr | 1,714.80 Cr | 699.60 Cr | 1,015.2000 Cr | 19.00 Cr | -375.50 Cr | 663.80 Cr | 323.30 Cr | 0.00 Cr | 0.00 Cr | 4.40 Cr | 651.3000 Cr |
2022-12-31 | 1,004.90 Cr | 2,071.70 Cr | 795.90 Cr | 1,275.8000 Cr | 23.60 Cr | -981.30 Cr | 408.00 Cr | 324.00 Cr | 4.70 Cr | 0.00 Cr | -4.30 Cr | 740.6000 Cr |
2021-12-31 | 1,538.00 Cr | 3,061.00 Cr | 835.40 Cr | 2,225.6000 Cr | 24.60 Cr | -1,513.40 Cr | 392.40 Cr | 341.70 Cr | 356.50 Cr | 0.00 Cr | -9.10 Cr | 749.6000 Cr |
2020-12-31 | 1,197.40 Cr | 2,918.50 Cr | 799.50 Cr | 2,119.0000 Cr | 22.60 Cr | -1,174.80 Cr | 368.00 Cr | 362.90 Cr | 356.10 Cr | 0.00 Cr | -24.90 Cr | 686.8000 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-12-31 | 461.5000 Cr | -19.2000 Cr | -392.4000 Cr | 425.1000 Cr | -110.7000 Cr | 283.8000 Cr | -36.4000 Cr | 562.4000 Cr | 0.0000 Cr | -384.6000 Cr | 68.7000 Cr |
2023-12-31 | 230.4000 Cr | 37.5000 Cr | -878.3000 Cr | 196.1000 Cr | -610.4000 Cr | 406.5000 Cr | -34.3000 Cr | 602.9000 Cr | 0.0000 Cr | -868.3000 Cr | -255.8000 Cr |
2022-12-31 | 398.7000 Cr | 650.9000 Cr | -1,582.7000 Cr | 376.5000 Cr | -533.1000 Cr | 1,004.9000 Cr | -22.2000 Cr | 864.3000 Cr | -8.0000 Cr | -1,573.0000 Cr | -31.4000 Cr |
2021-12-31 | 558.8000 Cr | 630.8000 Cr | -849.0000 Cr | 535.8000 Cr | 340.6000 Cr | 1,538.0000 Cr | -23.0000 Cr | 1,257.6000 Cr | -6.6000 Cr | -840.6000 Cr | -33.6000 Cr |
2020-12-31 | 611.1000 Cr | 276.4000 Cr | -810.0000 Cr | 569.7000 Cr | 77.5000 Cr | 1,197.4000 Cr | -41.4000 Cr | 677.2000 Cr | -4.6000 Cr | -803.8000 Cr | -22.2000 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2024-12-31 | 514.90 Cr | 249.80 Cr | 265.10 Cr | 0.5149 | 108.70 Cr | 91.30 Cr | 39.64 | 132.20 Cr | 0.1773 |
2024-09-30 | 524.00 Cr | 260.00 Cr | 264.00 Cr | 0.5038 | 110.70 Cr | 82.20 Cr | 35.69 | 122.00 Cr | 0.1569 |
2024-06-30 | 463.50 Cr | 290.30 Cr | 173.20 Cr | 0.3737 | 106.70 Cr | 103.20 Cr | 44.81 | 101.50 Cr | 0.2227 |
2024-03-31 | 732.40 Cr | 410.80 Cr | 321.60 Cr | 0.4391 | 208.90 Cr | 136.60 Cr | 59.31 | 198.70 Cr | 0.1865 |
2023-12-31 | 693.90 Cr | 382.40 Cr | 311.50 Cr | 0.4489 | 177.20 Cr | 137.70 Cr | 59.79 | 199.40 Cr | 0.1984 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2024-12-31 | 283.80 Cr | 56.20 Cr | 340.00 Cr | 0.00 Cr | 499.80 Cr | 1,126.80 Cr | 329.30 Cr | 1,611.80 Cr | 751.20 Cr |
2024-06-30 | 248.20 Cr | 14.70 Cr | 262.90 Cr | 179.80 Cr | 356.20 Cr | 876.80 Cr | 329.90 Cr | 1,360.30 Cr | 675.70 Cr |
2024-03-31 | -394.50 Cr | 789.00 Cr | 394.50 Cr | 0.00 Cr | 0.00 Cr | 394.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-12-31 | 406.50 Cr | 19.80 Cr | 406.50 Cr | 131.70 Cr | 663.80 Cr | 1,248.00 Cr | 323.30 Cr | 1,714.80 Cr | 699.60 Cr |
2023-09-30 | -448.10 Cr | 896.20 Cr | 448.10 Cr | 0.00 Cr | 0.00 Cr | 448.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2024-06-30 | 103.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 136.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-12-31 | 137.70 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-09-30 | 151.90 Cr | 19.80 Cr | 0.00 Cr | 0.00 Cr | 19.80 Cr | 467.90 Cr | 448.10 Cr | 0.00 Cr | 19.80 Cr |
2023-06-30 | 122.90 Cr | 19.60 Cr | 0.00 Cr | 0.00 Cr | 19.60 Cr | 448.10 Cr | 428.50 Cr | 0.00 Cr | 19.60 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
No split history data available. |
Similar Stocks: Drug Manufacturers - General
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Cipla Limited | CIPLA | ₹1,511.10 | ₹1,220,390,199,810.00 | ₹570,127.00 |
Abbott India Limited | ABBOTINDIA | ₹30,915.00 | ₹656,922,171,330.00 | ₹7,917.00 |
GlaxoSmithKline Pharmaceuticals Limited | GLAXO | ₹2,815.40 | ₹476,945,765,016.00 | ₹85,191.00 |
Gland Pharma Limited | GLAND | ₹1,464.40 | ₹241,269,301,448.00 | ₹333,283.00 |
Pfizer Limited | PFIZER | ₹4,191.40 | ₹191,747,043,905.00 | ₹21,385.00 |
Sanofi India Limited | SANOFI | ₹6,306.50 | ₹145,238,695,000.00 | ₹21,446.00 |
Marksans Pharma Limited | MARKSANS | ₹214.13 | ₹97,035,955,929.00 | ₹626,692.00 |
Key Executives
Gender: female
Year Born:
Gender: male
Year Born: 1955
Gender: male
Year Born:
Gender: male
Year Born: 1962
Gender: Not Specified
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1968
Gender: male
Year Born:
Gender: female
Year Born:
Gender: Not Specified
Year Born:
FAQs about Sanofi India Limited
The CEO is Mr. Rodolfo Hrosz.
The current price is ₹6,306.50.
The range is ₹4902-10524.95.
The market capitalization is ₹14,523.87 crores.
The dividend yield is 1.86%.
The P/E ratio is 35.14.
The company operates in the Healthcare sector.
Overview of Sanofi India Limited (ISIN: INE058A01010) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹14,523.87 crores and an average daily volume of 27,085 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹117.